Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (401-410 of 1,113) with videos related to

Pageof 112
Sort By:
Journal of the American College of Cardiology|January 18, 2020
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial FibrillationPhilippe Gabriel Steg, Gregory Ducrocq, Deepak L Bhatt, et al.
The Medical Journal of Australia|February 21, 2012
Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosisChristopher M Reid, Zanfina Ademi, Mark R Nelson, et al.
The Canadian Journal of Cardiology|November 25, 2011
The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)Hani Amad, Andrew T Yan, Raymond T Yan, et al.
Circulation. Cardiovascular Quality and Outcomes|October 2, 2014
β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trialSripal Bangalore, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology|March 14, 2020
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE TrialMichel Zeitouni, Anna Giczewska, Renato D Lopes, et al.
JAMA|August 29, 2012
Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarctionEtienne Puymirat, Tabassome Simon, Philippe Gabriel Steg, et al.
Archives of Cardiovascular Diseases|July 31, 2023
Association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease: Analysis from the CLARIFY registryJeremie Abtan, Gregory Ducrocq, Yedid Elbez, et al.
International Journal of Cardiology|April 28, 2015
Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromesNigel S Tan, Shaun G Goodman, Raymond T Yan, et al.
JACC. Advances|December 18, 2023
Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 TrialSiddharth M Patel, Marc P Bonaca, David A Morrow, et al.
Journal of the American College of Cardiology|August 15, 2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysisMichelle O'Donoghue, Elliott M Antman, Eugene Braunwald, et al.
Pageof 112

Showing results (401-410 of 1,113) with videos related to

Sort By:
Pageof 112
Journal of the American College of Cardiology|January 18, 2020
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial FibrillationPhilippe Gabriel Steg, Gregory Ducrocq, Deepak L Bhatt, et al.
The Medical Journal of Australia|February 21, 2012
Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosisChristopher M Reid, Zanfina Ademi, Mark R Nelson, et al.
The Canadian Journal of Cardiology|November 25, 2011
The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)Hani Amad, Andrew T Yan, Raymond T Yan, et al.
Circulation. Cardiovascular Quality and Outcomes|October 2, 2014
β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trialSripal Bangalore, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology|March 14, 2020
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE TrialMichel Zeitouni, Anna Giczewska, Renato D Lopes, et al.
JAMA|August 29, 2012
Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarctionEtienne Puymirat, Tabassome Simon, Philippe Gabriel Steg, et al.
Archives of Cardiovascular Diseases|July 31, 2023
Association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease: Analysis from the CLARIFY registryJeremie Abtan, Gregory Ducrocq, Yedid Elbez, et al.
International Journal of Cardiology|April 28, 2015
Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromesNigel S Tan, Shaun G Goodman, Raymond T Yan, et al.
JACC. Advances|December 18, 2023
Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 TrialSiddharth M Patel, Marc P Bonaca, David A Morrow, et al.
Journal of the American College of Cardiology|August 15, 2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysisMichelle O'Donoghue, Elliott M Antman, Eugene Braunwald, et al.
Pageof 112